OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.
The use of maintenance niraparib enhanced antitumor activity and led to a clinically meaningful increase in progression-free survival vs placebo for patients with newly diagnosed advanced ovarian cancer who displayed measurable residual disease after first-line platinum-based chemotherapy, according to findings from a post hoc subgroup analysis of the phase 3 PRIME study.
Treatment with tovorafenib elicited encouraging and fast onset responses in heavily pretreated pediatric patients with low-grade glioma regardless of response assessment criteria, according to data from the phase 2 FIREFLY trial that were presented at the 2023 ASCO Annual Meeting.
The protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 demonstrated preliminary antitumor activity and acceptable safety for patients with recurrent high-grade glioma and advanced or metastatic uveal melanoma, according to data from the dose-expansion portion of a phase 1 trial presented at the 2023 ASCO Annual Meeting.